Jaime B. Brugarolas

Hematology

5323 Harry Hines Blvd
Dallas, TX 75390

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 183 publications

A single chromosome 3p break initiates clear cell renal cell carcinoma evolution.

A single chromosome 3p break initiates clear cell renal cell carcinoma evolution.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

A single chromosome 3p break initiates clear cell renal cell carcinoma evolution.

A single chromosome 3p break initiates clear cell renal cell carcinoma evolution.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets.

A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets.

Journal: bioRxiv : the preprint server for biology

Published: July 03, 2026

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Journal: Cancer treatment reviews

Published: May 01, 2026

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Journal: Science translational medicine

Published: April 01, 2026

Correction: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Correction: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Journal: Oncogene

Published: March 04, 2026

Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer.

Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 04, 2026

Non-small Cell Lung Cancer in Metastatic Renal Cell Carcinoma Patients.

Non-small Cell Lung Cancer in Metastatic Renal Cell Carcinoma Patients.

Journal: Clinical genitourinary cancer

Published: January 21, 2026

Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.

Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.

Journal: Journal of kidney cancer and VHL

Published: January 15, 2026

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: January 09, 2026

Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.

Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: December 04, 2025

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Journal: medRxiv : the preprint server for health sciences

Published: December 03, 2025

Showing 1-12 of 183

Last Updated: 09/26/2026